Market News AIOpen the app

Pasithea Therapeutics Corp. faces potential delisting after failing to meet ongoing listing standards; listing transfer initiated (KTTA).

TroubleRead the original at sec.gov
Bad for KTTA

The company has received a notice of delisting, which could affect its stock price and trading status.

KTTA · Pasithea Therapeutics Corp.

AI read · Bad for KTTA

The AI's read

Pasithea filed an 8-K reporting a notice of delisting, so its Nasdaq listing and liquidity are at risk. Delisting threats are binary and can wipe out value or force a transfer to less liquid venues. Market action is weird: KTTA is up ~14.9% today, so traders are either betting on a rescue, a transfer, or short-covering. That pop reduces our edge because price action is going against the obvious negative read. We lean bearish because the filing is fresh and the core risk is clear: loss of listing damages access to capital and investor confidence. Conviction 84% — fresh catalyst but short-term sentiment noise makes timing unreliable.

Get alerts for KTTA

Follow Pasithea Therapeutics Corp. (KTTA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KTTA
Free on the App Store and Google Play, or on the web.